Gene Editing's Original Pioneer Just Got Sold for Parts

A few months later came another 40% workforce reduction, about 162 positions, plus the closure of its Brisbane, California headquarters. Management said the cuts would stretch the cash runway to Q3 2024. The stock was already sliding toward penny territory, trading near $0.54 a share.

Then, at the end of 2024, Pfizer pulled the plug on the hemophilia A gene therapy partnership, vaporizing access to $220 million in potential milestones. Sangamo's stock dropped 56% in a single day, landing at $1.02.

By the time Q1 2025 earnings hit, shares cratered another 42% after hours to $0.43. The company's quarterly revenue had collapsed from $158 million (Q1 2023) to $6.4 million. That's not a typo.

What Lilly and Astellas Are Getting

The bankruptcy filing came with two pre-arranged "stalking horse" bids, essentially minimum-price offers that set the floor at auction. Other buyers can try to outbid them, but these deals frame the likely outcome.

Eli Lilly is paying $50 million in cash (plus assumption of certain liabilities) for the crown jewels of Sangamo's technology stack:

• The AAV capsid delivery platform, which engineers viral shells to carry genetic payloads into specific tissues
• The zinc finger protein platform, Sangamo's foundational gene-editing technology
• The modular integrase (MINT) platform, a newer genome-editing system
• ST-506, a gene therapy for prion disease that uses Sangamo's blood-brain-barrier-crossing capsid tech

Astellas Pharma is paying $25 million upfront, with up to another $25 million in milestones, for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease that was approaching an FDA submission before the bankruptcy filing.

Several programs weren't included in either deal: a hemophilia A gene therapy with FDA Fast Track designation, a chronic pain program, and cell therapy assets. Those are still looking for buyers at auction.

The Clearance Rack Strategy

This is becoming a recognizable playbook. A biotech spends years and hundreds of millions building a technology platform. When the money runs out, Big Pharma doesn't acquire the company; it picks through the wreckage and buys individual assets at steep discounts.

Sangamo raised over $1 billion from pharma licensing fees, milestones, and equity investments over its lifetime. Its technology produced the first-ever in vivo gene editing in a human. And now its entire platform portfolio is selling for the price of a single Phase 1 clinical trial.

The pattern echoes what happened to bluebird bio, once valued above $10 billion. In February 2025, private equity firms Carlyle and SK Capital bought the whole company (three approved gene therapies included) for just $29 million in cash plus milestone-linked payments.

For large pharma, bankruptcy courts are becoming a legitimate sourcing channel. Section 363 sales let buyers acquire assets free and clear of debts and liens, which is corporate-speak for "no baggage." It's like buying a house at foreclosure auction: same property, fraction of the price.

What This Means for Gene Therapy

Sangamo's bankruptcy doesn't mean its science was bad. It means the economics of being a small, pre-revenue gene therapy company in a high-rate environment are nearly impossible to sustain. The company burned through cash faster than it could generate milestones, and each partnership termination accelerated the spiral.

Lilly now controls a 30-year zinc finger patent estate and a suite of delivery technologies for a price that wouldn't buy a luxury condo building in Manhattan. Astellas gets a near-filing-ready Fabry disease therapy for what amounts to a rounding error on its balance sheet.

The 77 employees Sangamo retained to keep the lights on during bankruptcy are working to preserve value for the auction. But for the 51 who were laid off (roughly 40% of the remaining team), and for the shareholders who watched a once-$10-billion-in-potential-milestones company dissolve, the lesson is brutal.

In biotech, being first doesn't mean you finish. Sometimes it just means you're building the inventory for someone else's shopping spree.